Podcasts about clinical trials

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

LINK TO ACRO'S RBQM SUMMARY REPORT: https://www.acrohealth.org/rbqm-summary-report/In this episode, ACRO RBQM Working Group members Lauren Garson (Veeva), Cris McDavid (Parexel), and Jennifer Stewart (Premier Research) joined ACRO's Good Clinical Podcast to discuss key takeaways from ACRO's annual RBM/RBQM Landscape Survey. Since 2019, ACRO's RBQM survey has dug into trial-level data on industry adoption of RBM and RBQM components. Informed by conversations with FDA, the aim of the survey is to evaluate ACRO member companies' adoption of risk-based monitoring to better understand how the larger framework of risk-based quality management (RBQM) are being adopted across the clinical trial industry.  

Send us a textAI promises to revolutionize clinical trials and reshape regulatory oversight. But is the pharma industry ready? And can the FDA keep pace with the technology? In this episode of the HealthBiz Podcast, host David Williams is joined by Tom Doyle, Chief Technology Officer of Medidata, to discuss the promises and potential pitfalls of AI in clinical trials.

Send us a textSteve Satek joins Dr. Michael Koren to share his journey from bench researcher to founding his own community clinical trial site. The entrepreneur describes how he pioneered embedding clinical research directly in Chicago neighborhoods to form a strong integration with the community. He talks about the importance of building trust through education and by helping the community where you are. They talk about how a strong relationship with your community members is vital to the success of research and patient outcomes.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Julio Martinez-Clark, Co-Founder and CEO of Bioaccess, a Latin American MedTech CRO that works with US-based medtech and biopharma startups to conduct their first-in-human trials outside the US to accelerate development and recruitment. Data from overseas clinical trials conducted to international standards is considered valid and can support conversations with investors, strategic partners, and the FDA. Drawing on resources in the Balkans, Latin America, and Australia, clinical trials can get faster approvals, more easily recruit patients, and benefit those living in the communities where clinical trials are conducted.   Julio explains, "The mission is to accelerate global clinical trials, and the type of clients is mostly us. Occasionally, we have European clients, but they're mostly San Francisco-based, Boston-based, San Diego-based, Minnesota-based, or Boston-based companies that are looking to execute a first-in-human clinical study outside of the United States. And for many reasons, Latin America is an obvious choice, at least for the exploratory phase. When they're looking for different countries, they usually explore Eastern Europe, Australia, and Latin America. And we help these companies, which have been predominantly US-based MedTech startups. More recently, we have expanded to biopharma as well. But let's talk with the conversation on MedTech startups, and their struggle to conduct these first inhuman trials in the United States. They seek help when they want to go overseas, and they call for us to help them find investigators and to recruit patients and to get past approvals, etc." "There is one single thing, which is that these companies are startups. Getting this type of trial approved is really, really difficult and expensive. And the timeline to get them approved is really uncertain. So when you have a startup that has investors backing the company and they have a business plan, they have some milestones, it is difficult to predict when you're going to hit these milestones, and you need to keep the investors happy. So if you don't have a solid business plan, then you are not going to be able to raise more funds to continue your operation and development."  #BioAccess #GlobalTrialAccelerators #DigitalHealth #PrecisionMedicine #LATAMTrials #BalkansClinicalResearch #AustraliaCTN #AANVISA #ALIMS #MINSA #TrialAcceleration #FirstinHumanTrials #ClinicalTrials #MedTechInnovation #Biopharma #MedTech #PatientRecruitment #CRO bioaccessla.com Download the transcript here

Julio Martinez-Clark, Co-Founder and CEO of Bioaccess, a Latin American MedTech CRO that works with US-based medtech and biopharma startups to conduct their first-in-human trials outside the US to accelerate development and recruitment. Data from overseas clinical trials conducted to international standards is considered valid and can support conversations with investors, strategic partners, and the FDA. Drawing on resources in the Balkans, Latin America, and Australia, clinical trials can get faster approvals, more easily recruit patients, and benefit those living in the communities where clinical trials are conducted.   Julio explains, "The mission is to accelerate global clinical trials, and the type of clients is mostly us. Occasionally, we have European clients, but they're mostly San Francisco-based, Boston-based, San Diego-based, Minnesota-based, or Boston-based companies that are looking to execute a first-in-human clinical study outside of the United States. And for many reasons, Latin America is an obvious choice, at least for the exploratory phase. When they're looking for different countries, they usually explore Eastern Europe, Australia, and Latin America. And we help these companies, which have been predominantly US-based MedTech startups. More recently, we have expanded to biopharma as well. But let's talk with the conversation on MedTech startups, and their struggle to conduct these first inhuman trials in the United States. They seek help when they want to go overseas, and they call for us to help them find investigators and to recruit patients and to get past approvals, etc." "There is one single thing, which is that these companies are startups. Getting this type of trial approved is really, really difficult and expensive. And the timeline to get them approved is really uncertain. So when you have a startup that has investors backing the company and they have a business plan, they have some milestones, it is difficult to predict when you're going to hit these milestones, and you need to keep the investors happy. So if you don't have a solid business plan, then you are not going to be able to raise more funds to continue your operation and development."   #BioAccess #GlobalTrialAccelerators #DigitalHealth #PrecisionMedicine #LATAMTrials #BalkansClinicalResearch #AustraliaCTN #AANVISA #ALIMS #MINSA #TrialAcceleration #FirstinHumanTrials #ClinicalTrials #MedTechInnovation #Biopharma #MedTech #PatientRecruitment #CRO bioaccessla.com Listen to the podcast here  

Dr. David Furman and Dr. Buck Joffrey discuss the complexities of immune aging, the role of inflammation in age-related diseases, and how artificial intelligence is being utilized to enhance research in this field. He introduces the concept of the inflammatory age clock, which measures biological aging through immune system signals, and explores potential therapeutic interventions, including nutraceuticals and therapeutic plasma exchange. The discussion also touches on the future of aging research, emphasizing personalized approaches and the democratization of diagnostics. Learn more about Dr. David Furman: https://www.buckinstitute.org/lab/furman-lab/

Send us a textDr. Koren reflects on conversations with Harvard Medical School classmates who shared stories about struggling to navigate the healthcare system despite their medical training. Clinical trials provide valuable structure and support to help patients navigate healthcare complexities, offering personalized attention often unavailable in traditional medical settings.• Harvard Medical School graduates find healthcare navigation difficult, highlighting challenges for average patients• Case study of 78-year-old with heart failure who was accidentally overdosed on medications after discharge• Clinical trials break down complex health information into clear protocols • Research coordinators help patients understand treatments and communicate with other providers• Studies available for congestive heart failure patients, including both types of heart failure• Harvard classmates will be featured on upcoming MedEvidence episodesVisit EncoreDocs.com to learn more about participating in clinical trials, or call 904-730-0166. For reliable medical information, check out MedEvidence.com - the truth behind the data, a better alternative to "Dr. Google."Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In 2024, ACRO announced its D&I Site Resource Grants Program. Designed to support an innovative 12-month pilot project, the site resource grants act as a platform to incubate innovative strategies for improving representative enrollment in clinical research.  On this episode, site grantee representatives Dr. Ammara Mushtaq, MD (Brooklyn Clinical Research), Dr. Lovie Negrin, APRN (Randomize Now), and Sandra Carmona Torres, BSN (K2 Medical Research) join the podcast to discuss the lessons learned through implementing their pilot projects so far. They dive deeper into how sites can address barriers to participation, the need for consistent investment in building trust and engaging local community members, and the state of clinical research from a site perspective.

Send us a textDr. Michael Koren interviews Lavern Dowell, an advanced registered nurse practitioner who specializes in diabetes care. They discuss her approach to treating the whole person and how mental health can impact everything from diet and exercise to the ability to go see a physician. They also emphasize the need to increase diversity in medical research and the importance of delivering diagnoses with sensitivity to avoid causing shame to patients.Learn more about Lavern's practice here: https://www.dowellmedical.org/Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Vaccines have become one of the most polarizing topics in public health, and frankly, for valid reasons. What we've witnessed over the past few years is an unprecedented breakdown in trust between medical institutions and the public - and that didn't happen in a vacuum.What is the truth about Vaccine Safety and Efficacy? Dr. Roger McFillin sits down with vaccine safety epidemiologist Allison Krug to expose the hidden forces shaping public health, from vaccine safety to the weaponization of fear. They dive deep into the failures of placebo-controlled trials, the truth about natural immunity vs. vaccine-induced immunity, and why good evidence is harder to find than you think. Allison shares what she learned working inside the pharmaceutical industry and reveals how mindset, belief systems, and disconnection from nature and spirituality are fueling today's chronic illness crisis. If you've ever questioned mainstream medicine or want to reclaim your health and autonomy, this conversation will change how you see the world.00:00 Introduction00:05:32 The Danger of Outsourcing Health to "Experts"00:20:45 Mindset, Pain, and the Illusion of Powerlessness00:42:49 Consciousness and the Healing Power Within01:05:32 Germ Theory, Genetics, and the Loss of Agency01:15:47 Awakening to Frequencies: A Spiritual Revolution01:22:23 Dark Spiritual Forces and the Battle for Consciousness01:31:27 How Public Schools Crush Creativity and Independence01:49:05 Medical Paradigm Flaws: What They're Not Telling You01:55:40 Spiritual Emptiness: The Hidden Cost of Modern Culture02:00:12 Radical Responsibility and the Return to Divine LoveAllision Krug WebsiteAllision Krug on XAllison Krug on Megyn Kelly COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities  Dr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

In this episode of “Moving Medicine Forward,” host Jeremy Strand sits down with Brian Lawrence, Chief Financial Officer at CTI, to explore how strategic financial planning is critical to advancing clinical trials, particularly in rare disease research. Brian shares insights on balancing profitability with purpose in one of the world's most highly regulated industries, reflecting on early career decisions, global expansion, trial funding challenges, and the growing influence of AI in finance. 00:36 Brian shares how early interests in math and accounting, along with a few great mentors, led him into finance and the clinical research space. 02:17 Why Brian opted for a smaller accounting firm over a Big Four company and how that decision shaped his career. 03:16 How his love for process improvement and early experiences with digital transformation prepared him for the dynamic contract research organization (CRO) environment. 04:03 Brian discusses CTI's evolution: growing four times in size, expanding globally, and staying true to its rare disease focus. 05:00 The challenge of maintaining profitability while upholding the highest standards in research and compliance. 06:00 Brian explains the hidden costs of operating globally, including banking, compliance, and cybersecurity.  07:10 Why financial planning is critical in biotech, where projects can be halted suddenly due to safety or funding concerns. 09:00How investment trends and economic shifts post-COVID have tightened budgets and forced CROs and sponsors to adapt. 10:00 Brian breaks down the financial implications of trial diversity, especially in rare diseases with complex study designs. 11:12 The role of AI and digital tools in modern CRO operations, and why CTI is taking a deliberate approach to adoption. 13:00 Brian sees technology as a way to eliminate low-value tasks and empower finance teams to focus on strategic insights. 14:00 Through initiatives like CTI Cares and “Mission Moments,” Brian explains how CTI connects internal teams to the bigger picture of patient impact. 

Explore key aspects of aging and menopause, focusing on women's health and how biological changes impact overall well-being. Experts discuss current research on healthy aging, including the role of physical activity, brain health, and hormone changes during menopause. They highlight how sex differences affect diseases like Alzheimer's and emphasize the importance of personalized approaches to treatment and prevention. The presentation also underscores ongoing studies and resources aimed at improving the quality of life for aging women through better understanding and support Linda Brubaker, M.D.,M.S. Clinical Landscape and OGRS Opportunities Amanda Lewis, Ph.D. Glycobiology (GLOW) Andrea LaCroix, Ph.D. Healthy Aging After Menopause Anthony Molina, Ph.D. Stein Institute for Research on Aging Sarah Banks, Ph.D. Alzheimer in Women Emily Lukacz, M.D.,M.A.S. Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium and Pelvic Floor Disorders Network (PFDN) Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40668]

Explore key aspects of aging and menopause, focusing on women's health and how biological changes impact overall well-being. Experts discuss current research on healthy aging, including the role of physical activity, brain health, and hormone changes during menopause. They highlight how sex differences affect diseases like Alzheimer's and emphasize the importance of personalized approaches to treatment and prevention. The presentation also underscores ongoing studies and resources aimed at improving the quality of life for aging women through better understanding and support Linda Brubaker, M.D.,M.S. Clinical Landscape and OGRS Opportunities Amanda Lewis, Ph.D. Glycobiology (GLOW) Andrea LaCroix, Ph.D. Healthy Aging After Menopause Anthony Molina, Ph.D. Stein Institute for Research on Aging Sarah Banks, Ph.D. Alzheimer in Women Emily Lukacz, M.D.,M.A.S. Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium and Pelvic Floor Disorders Network (PFDN) Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40668]

Explore key aspects of aging and menopause, focusing on women's health and how biological changes impact overall well-being. Experts discuss current research on healthy aging, including the role of physical activity, brain health, and hormone changes during menopause. They highlight how sex differences affect diseases like Alzheimer's and emphasize the importance of personalized approaches to treatment and prevention. The presentation also underscores ongoing studies and resources aimed at improving the quality of life for aging women through better understanding and support Linda Brubaker, M.D.,M.S. Clinical Landscape and OGRS Opportunities Amanda Lewis, Ph.D. Glycobiology (GLOW) Andrea LaCroix, Ph.D. Healthy Aging After Menopause Anthony Molina, Ph.D. Stein Institute for Research on Aging Sarah Banks, Ph.D. Alzheimer in Women Emily Lukacz, M.D.,M.A.S. Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium and Pelvic Floor Disorders Network (PFDN) Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40668]

Roxana Mehran speaks with Scott Solomon about where the field's at and what the future holds.

On the phone-in: Our guests Bradley Paul and Heather Stevens discuss the growth in the Indigenous tourism sector. And off the top of the show, we hear from Diana Moser who's part of the clinical trials for a vaccine against Lyme disease. We also hear your feedback on alcohol in corner stores in NS and the possible increase in mining in the Maritimes.

Explore key aspects of aging and menopause, focusing on women's health and how biological changes impact overall well-being. Experts discuss current research on healthy aging, including the role of physical activity, brain health, and hormone changes during menopause. They highlight how sex differences affect diseases like Alzheimer's and emphasize the importance of personalized approaches to treatment and prevention. The presentation also underscores ongoing studies and resources aimed at improving the quality of life for aging women through better understanding and support Linda Brubaker, M.D.,M.S. Clinical Landscape and OGRS Opportunities Amanda Lewis, Ph.D. Glycobiology (GLOW) Andrea LaCroix, Ph.D. Healthy Aging After Menopause Anthony Molina, Ph.D. Stein Institute for Research on Aging Sarah Banks, Ph.D. Alzheimer in Women Emily Lukacz, M.D.,M.A.S. Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium and Pelvic Floor Disorders Network (PFDN) Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40668]

Explore key aspects of aging and menopause, focusing on women's health and how biological changes impact overall well-being. Experts discuss current research on healthy aging, including the role of physical activity, brain health, and hormone changes during menopause. They highlight how sex differences affect diseases like Alzheimer's and emphasize the importance of personalized approaches to treatment and prevention. The presentation also underscores ongoing studies and resources aimed at improving the quality of life for aging women through better understanding and support Linda Brubaker, M.D.,M.S. Clinical Landscape and OGRS Opportunities Amanda Lewis, Ph.D. Glycobiology (GLOW) Andrea LaCroix, Ph.D. Healthy Aging After Menopause Anthony Molina, Ph.D. Stein Institute for Research on Aging Sarah Banks, Ph.D. Alzheimer in Women Emily Lukacz, M.D.,M.A.S. Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium and Pelvic Floor Disorders Network (PFDN) Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40668]

Explore key aspects of aging and menopause, focusing on women's health and how biological changes impact overall well-being. Experts discuss current research on healthy aging, including the role of physical activity, brain health, and hormone changes during menopause. They highlight how sex differences affect diseases like Alzheimer's and emphasize the importance of personalized approaches to treatment and prevention. The presentation also underscores ongoing studies and resources aimed at improving the quality of life for aging women through better understanding and support Linda Brubaker, M.D.,M.S. Clinical Landscape and OGRS Opportunities Amanda Lewis, Ph.D. Glycobiology (GLOW) Andrea LaCroix, Ph.D. Healthy Aging After Menopause Anthony Molina, Ph.D. Stein Institute for Research on Aging Sarah Banks, Ph.D. Alzheimer in Women Emily Lukacz, M.D.,M.A.S. Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium and Pelvic Floor Disorders Network (PFDN) Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40668]

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

With so many treatment modalities for upper tract urothelial carcinoma, how does new evidence inform optimal care? In this episode of BackTable Tumor Board, urologic oncologist Dr. Nirmish Singla (Johns Hopkins), medical oncologist Dr. Jeannie Hoffman-Censits (Johns Hopkins), and urologic oncologist Dr. Bogdana Schmidt discuss treatment and diagnosis of upper tract urothelial carcinoma (UTUC). --- This podcast is supported by: Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1 --- SYNPOSIS The discussion covers real-world UTUC cases, highlighting diagnostic challenges, treatment options, and evidence-based management strategies. They address scenarios ranging from localized to advanced UTUC, the role of systemic therapies, perioperative treatments, and the potential for novel approaches with immune checkpoint inhibitors. The episode underscores the evolving landscape of UTUC treatment and the importance of clinical trials and emerging biomarkers in improving patient outcomes. --- TIMESTAMPS 00:00 - Introduction 02:49 - Case Study 1: 66-Year-Old Male with UTUC11:19 - Case Study 2: 73-Year-Old Male with High-Grade Urothelial Carcinoma28:11 - Intravesical Chemotherapy Protocols30:44 - Case Study 3: 57-Year-Old Male with Recurrent Urothelial Cancer41:25 Clinical Trials and Emerging Treatments45:40 Case Study: 55-Year-Old Female with Bulky Lymphadenopathy 56:45 Concluding Remarks and Future Directions --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

In today's episode, we spoke with Jonathan W. Goldman, MD, about the phase 2 LUMINOSITY study (NCT03539536) evaluating telisotuzumab vedotin-tllv (Teliso-V; Emrelis) in patients with c-MET protein–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). Dr Goldman is a professor of medicine in the Division of Hematology/Oncology at UCLA, as well as director of Clinical Trials in Thoracic Oncology, associate director of Early Drug Development, and chair of the University of California Lung Cancer Consortium.

In this episode, Jonathan Norman (Director, Localisation Services, YPrime) and Laura Russell (Senior Vice President, Head of Data and AI Product Development, Advarra) join the podcast to discuss how artificial intelligence is transforming today's clinical operations. They dive deeper into how AI can be used to improve protocol design, drive efficiency in localization processes, and modernize clinical operations to expand access to trials and get treatments to patients sooner. 

With Kevin Damman, University Medical Center Groningen, Groningen - The Netherlands, Floran Sahiti, University Hospital of Wurzburg, Wurzburg - Germany, Joao Pedro Ferreira, University of Porto, Porto - Portugal, Novi Yanti Sari, Siloam Hospitals Group, Jakarta - Indonesia, Marat Fudim, Duke University Medical Center, Durham, NC - USA, Gregorio Tersalvi, Mayo Clinic, Rochester, MN - USA, Jose Luis Morales Rull, University Hospital Arnau de Vilanova, Lleida - Spain and Cornelia Margineanu, Bucharest - Romania. In this episode, we discuss four late-breaking clinical trials presented at the Heart Failure Congress 2025 in Belgrade, Serbia. First, Kevin Damman presents the results of FUTURE-HF, a first-in-human study evaluating the long-term safety, accuracy, and clinical utility of a novel implantable IVC sensor for remote heart failure management. Next, Joao Pedro Ferreira highlights the key findings of SOGALDI-PEF, a crossover trial comparing SGLT2 inhibitor monotherapy versus combination therapy with an SGLT2 inhibitor and a mineralocorticoid receptor antagonist (MRA) in reducing NT-proBNP levels. Third, Marat Fudim reports on the MUSIC-HFpEF phase 1/2a trial, which explores the safety and preliminary efficacy of a novel gene therapy using adeno-associated virus vectors in patients with HFpEF. Finally, Jose Luis Morales Rull shares insights from PREFER-HF, a study assessing the effects of intravenous or oral iron therapy versus placebo in patients with HFpEF and iron deficiency anemia. FUTURE-HF: Long-term safety, accuracy, and utility of a novel implantable IVC sensor for remote HF management - Kevin Damman, University Medical Center Groningen, Groningen, The Netherlands. Host: Floran Sahiti, University Hospital of Wurzburg, Wurzburg, Germany doi: 10.1016/j.jchf.2025.01.019. SOGALDI-PEF: SOdium-Glucose cotransporter 2 inhibitor with and without an ALDosterone AntagonIst for heart failure with preserved ejection fraction – Joao Pedro Ferreira, University of Porto, Porto, Portugal. Host: Novi Yanti Sari, Siloam Hospitals Group, Jakarta (Indonesia).  MUSIC-HFpEF: Gene therapy in Heart Failure with Preserved Ejection Fraction – Marat Fudim, Duke University Medical Center, Durham, NC, USA. Host: Gregorio Tersalvi, Mayo Clinic, Rochester, MN, USA PREFER¬-HF: Effects intravenous iron or oral iron therapy compared to placebo in HFpEF with iron deficiency anemia - Jose Luis Morales Rull, University Hospital Arnau de Vilanova, Lleida, Spain. Host: Cornelia Margineanu, Bucharest, Romania. This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

Julio G. Martinez-Clark CEO of Bioaccess and President of IAOCR/GCSA Americas is a MedTech trailblazer helping startups accelerate First-in-Human (FIH) clinical trials across Latin America, with over 20 years of experience spanning healthcare, telecom and venture capitalIn this episode, we unpack why more MedTech companies are turning to LATAM for faster, more cost-effective trial execution. Julio shares how his Miami-based CRO helps deliver 58-day CE mark approvals, his experience supporting 100+ device startups and why time, not money, is the most precious currency for early-stage founders. We also touch on trial quality, regulatory strategy and why he believes Latin America will play a defining role in the next era of global MedTech innovationTimestamps:[00:00:47] Why LATAM Is the Next MedTech Trial Hub[00:02:21] The Problem with FIH Trials in the U.S.[00:04:42] How bioaccess® Reduces Approval Timelines by 70%[00:06:01] Strategic Sites, Patient Retention & CRO Infrastructure[00:08:17] Do LATAM Trials Hold Up to FDA & EU Scrutiny?[00:10:43] The Fundraising Pressure Behind Faster Clinical Results[00:12:22] Founder Mistakes in In-House Trial Management[00:14:11] Why LATAM May Overtake Eastern Europe in FIH Volume[00:17:26] Regulatory Standards, UNESCO, and Regional Quality[00:20:10] Julio Outside the Office: Family, Fitness & PodcastingGet in touch with Julio - https://www.linkedin.com/in/juliomartinezclark/Learn more about Bioaccess - https://www.bioaccessla.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

Send us a textDr. Michael Koren joins Kevin Geddings to discuss the motivations of clinical trial veterans who repeatedly participate in medical research studies. Dr. Koren shares that these participants consistently cite the desire to "Make a Difference" as their primary motivation, pushing science and medicine forward for generations to come.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Carol Harvey's powerful journey from experienced nurse to breast cancer survivor offers a unique dual perspective that changes everything.Carol shares her unexpected triple-negative breast cancer diagnosis in September 2020 during the height of COVID restrictions when family couldn't accompany her to treatments. With 35 years of nursing experience and a role teaching future nurses at Liberty University, Carol brought professional knowledge to her patient experience that provided both advantages and surprising challenges.Her decision to join a clinical trial stands as perhaps the most fascinating aspect of this conversation. Despite her medical background, Carol experienced the vulnerability all patients feel when considering experimental treatments. The outcome? Extraordinary monitoring that included multiple echocardiograms, rapid tumor response, and a comprehensive team approach that left her feeling exceptionally well-cared for. "If I were to go through the whole thing again, I would jump into a clinical trial again, 100%," she reflects.Through chemotherapy, surgery, radiation, and even cognitive therapy for "chemo brain," Carol's journey spans numerous departments within Centra Health. Now three years post-treatment with regular follow-ups, she finds herself transformed. "I am such a better person on this side of cancer than I was beforehand," she reveals, describing a deeper faith, greater empathy, and profound perspective shift that turns even "bad hair days" into moments of gratitude. Her powerful closing message resonates for anyone facing difficult circumstances: "I can do hard things." Listen now to experience this remarkable story of professional insight meeting personal transformation.For more content from Centra Health check us out on the following channels.YouTubeFacebookInstagramTwitter

This episode focuses on how IQVIA is innovating with agentic AI to drive efficiency and quality in clinical trials.  In this episode you will:   Discover how agentic AI can be leveraged to enhance efficiency and quality in clinical trials and help increase the chance of success. See how an agentic AI approach can optimize site selection, trial design, and other critical elements in clinical trials. Learn about using agentic AI to identify new indications and targets in early clinical development by analyzing data from multiple databases. Speaker: Raja Shankar, Vice President of Machine Learning in IQVIA's Research and Development Solutions.

Expanding access to clinical trials in community oncology settings is essential to improving diversity, equity, and inclusion in cancer research. In this episode, CANCER BUZZ speaks with clinical research coordinator, Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP, whose cancer center recently participated in a foundational oncology clinical trials course, developed by ACCC and the Association of Clinical Research Professionals (ACRP) to help cancer programs expand availability of trials to traditionally underserved communities. Oladipupo shares how this training prepared their center for the challenges of a growing research program, the progress they've made, and the pivotal role of clinical research coordinators in expanding research programs and improving patient access to clinical trials.   Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP Clinical Research Coordinator Touro-Cancer Center New Orleans, LA   “We know that diversity is a big point, not only as per new FDA guidance, but [to] ensure that every participant is given an equal opportunity to hear about the study. [Our] approach is not to target a certain group of individuals. Really the approach is to target any individual that looks potentially eligible.” - Oluwakemi “Kemi” Oladipupo   Resources:  Community Oncology Can Close the Gap in Cancer Research Increasing Clinical Trial Accrual Through the Implementation of a Clinical Trials Navigator The Role of the Clinical Trials Navigator — [MINI PODCAST] EP 129 Human-Centered Design: A Possible Solution to Rural Clinical Trial Enrollment

Register free at https://brightu.com to watch the full Healing Revolution stream - Breaking News and Upcoming Segments (0:00) - Microscopy of Bio Sludge (2:04) - Bio Sludge as a Vector for Bioterrorism (4:03) - Details of the Chinese Couple's Case (7:23) - Potential for Bioterrorism and EPA's Role (11:51) - Microscopy of Bio Sludge: Dry Condition (17:54) - Microscopy of Bio Sludge: Incubated Condition (39:25) - Moderna Vaccine Approval and RFK Jr. (53:26) - Elon Musk's Criticism of Trump's Bill (1:07:07) - Ukraine War and Financial Corruption (1:12:41) - AI and Humanity's Future (1:17:40) - Self-Awareness in Life Forms (1:20:40) - Artificial Intelligence and Self-Awareness (1:27:51) - The Potential Dangers of AI (1:32:30) - AI's Impact on Infrastructure and Society (1:37:07) - The Role of Light in Healing (1:46:09) - The Healing Revolution Docu Series (1:47:06) - The Importance of Combining Therapies (1:50:03) - The Role of Light in Activating Nutrients (1:51:34) - The Impact of Light on Cancer Treatment (2:33:08) - The Role of Light in Detoxification (2:35:26) - LED vs. Incandescent/Halogen Bulbs (2:36:33) - Wavelengths and Their Therapeutic Benefits (2:38:13) - Dual LED Technology and Natural Intelligence (2:39:45) - Practical Applications and Humanitarian Efforts (2:42:09) - Healing Revolution Course and Additional Resources (2:45:53) - Long COVID Study and Remission Rates (2:47:42) - Final Thoughts and Call to Action (2:50:30) - Health Ranger's Preparedness Tips (2:51:47) - Iodine Supplements and Their Benefits (2:56:14) - Conclusion and Final Remarks (2:58:12) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Today's guest is Xiong Liu, Director of Data Science and AI at Novartis. Xiong returns to the platform in a special episode brought to you by Medable to explore the evolving role of AI in modernizing clinical trials. Their conversation covers how life sciences teams are leveraging AI to streamline data workflows, accelerate study readiness, and maintain regulatory compliance in both decentralized and traditional models. Throughout the episode, Xiong shares insights into the growing importance of integrating structured and unstructured data across trial systems — from clinical notes to imaging and lab results. This episode is sponsored by Medable. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

Europe Notified Body survey report - 31 October 2024 - What is the main Surprise: https://health.ec.europa.eu/document/download/59b9d90e-be42-4895-9f6f-bec35138bb0a_en?filename=md_nb_survey_certifications_applications_en.pdf The MIR form has been updated - Version 7.3.1 - Don't use previous versions: https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance/pmsv-reporting-forms_en   UK: UK MIR and FSCA - Change is in the AIR: https://www.gov.uk/government/publications/more-implementation/gb-mir-and-fsca-schema-implementation-guide UK MDR 2002 is dying - Long life to UK MDR 2025: https://www.legislation.gov.uk/ukdsi/2025/9780348269529 : Real-World Data or Clinical Trial or Both?- This is the question: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions     Training EU MDR Green Belt June 2025 - June 23rd, June 27th: https://school.easymedicaldevice.com/course/gb34/ eTraining on Vigilance and Audit preparation - Self-paced: https://school.easymedicaldevice.com/emd-course   ROW USA Q-Sub update  - New electronic template: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-medical-device-q-submissions   Brazil: SIUD or UDI in Brazil - Manual of Use in Portuguese: https://www.gov.br/anvisa/pt-br/assuntos/produtosparasaude/temas-em-destaque/arquivos/manual_siud_v01.pdf   Saudi Arabia: Series of Webinar - June is a Busy month in Saudi Arabia: 16 June 2025 Companion Diagnostic Regulatory Requirements: https://www.sfda.gov.sa/en/workshop/3540492 17 June 2025 Saudi Unique Device Identification (SAUDI-DI): https://www.sfda.gov.sa/en/workshop/3540493 19 June 2025 Artificial Intelligence and Machine Learning: https://www.sfda.gov.sa/en/workshop/3540495 23 June 2025 Digital Health Medical Devices regulatory approach: https://www.sfda.gov.sa/en/workshop/3540496 24 June 2025 Medical Devices Risk Classification: https://www.sfda.gov.sa/en/workshop/3540497 Saudi In-house Devices - Not like EU: https://www.sfda.gov.sa/sites/default/files/2025-05/MDS-G022En.pdf   Turkey: In Turkey, Economic Operators are Liable - Even after discontinuation or temporary stop of supply: https://titck.gov.tr/duyuru/tibbi-cihazlarin-tedarikinin-kesintiye-ugramasi-veya-durdurulmasi-sona-ermesi-durumunda-i-ktisadi-i-sletmecilerin-yukumlulukleri-hakkinda-duyuru-21052025113350   PODCAST: Podcast Nostalgia - What happened in May 2025 Episode 334 - What is the new UK Post-Market Surveillance Requirements? With Claire Dyson: https://podcast.easymedicaldevice.com/334-2/ Episode 335 - When is Regulatory Affairs needed during Design? With Aouda Ouzza: https://podcast.easymedicaldevice.com/335-2/ Episode 336 - is EHDS dangerous for Medical Device Manufacturers? With Cecile van der Heijden: https://podcast.easymedicaldevice.com/336-2/ Episode 337 - How Deepeye Medical overcame the AI Act? With Carmen Bellebna; https://podcast.easymedicaldevice.com/337-2/ Episode 338 - Trapped or Strategic? Changing Notified Bodies During MDR transition: https://podcast.easymedicaldevice.com/338-2/  

Julio Martinez-Clark teamed up with his cardiologist brother and other doctors to help speed up the clinical trials part of the process. Julio's team at bioaccess® is moving medicine forward quicker by helping startups and researchers get the data from clinical trials in other countries. Advancements can now come to market quicker while also helping suffering people in countries that do not have the means to afford the proper medical care. This saves time, money, and people.Julio Martinez-Clark is the co-founder and CEO of bioaccess®. Julio believes Latin America is an untapped destination for Medtech clinical research. Since 2010, Julio has supported +100 Medtech in operationalizing successful clinical trials in several countries in Latin America. Julio was the chairman of the board of the Association for the Advancement of Clinical Research in Colombia (AVANZAR). Julio writes a column at Med Device Online, where his articles have been "Featured Editorials" on several occasions. Julio hosts the LATAM Medtech Leaders podcast, interviewing Medtech leaders who have succeeded in Latin America.Julio has a wealth of experience in various fields, including serving as an advisor to the CEO of Amavita Heart and Vascular Health™, the most extensive cardiovascular practice in South Florida, an advisor to government agencies in Colombia looking to position the country as a clinical trial destination, and a mentor to startups at Macondo Labs, a top incubator in Colombia.Learn more at www.bioaccessla.com and connect with Julio on Linkedin @juliomartinezclark Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

Send us a textDr. Nikhil Kapila joins Dr. Michael Koren on this live MedEvidence! presentation. Dr. Kapila, a liver disease specialist, explains why we can't live without our liver. The doctors review what the liver does, what can cause damage to the liver, and what can go wrong when the liver suffers damage. They also discuss the importance of early testing, treatment options for some conditions, and the importance of clinical research in pushing liver health forward.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Jamal Khan and Jennifer Johnson as they explore the evolving landscape of AI in healthcare, focusing on its applications, ethical considerations, data privacy, and the role of Chief AI Officers. This discussion highlights the importance of governance, patient consent, and the potential of AI to improve healthcare workflows while addressing data security challenges. Learn about how to implement AI responsibly for better healthcare outcomes and operational excellence.  Speakers: Jamal Khan, Chief Growth and Innovation Officer at Connection Jennifer Johnson, Director of Healthcare Strategy and Business Development at Connection   Show Notes: 00:00 The Evolution of AI in Healthcare 03:04 Ethics and Governance in AI Applications 06:05 Data Privacy and Security Concerns 08:49 The Role of Chief AI Officers 12:07 Patient Consent and Data Usage 14:54 AI's Impact on Healthcare Workflows 18:00 Computational Power in Health Data Analysis 20:47 Virtual Assistants in Healthcare 24:00 Clinical Trials vs. Drug Discovery 26:55 The Future of Patient Data Management 28:11 AI Adoption in Insurance Companies 33:05 Transparency and Explainability in AI 37:28 AI Use Cases in Healthcare 44:10 Cloud vs On-Prem AI Solutions 49:23 Data Orchestration in Healthcare   For more information on AI services for healthcare, visit https://www.cnxnhelix.com/healthcare.     

We welcome Karla Childers to AI Uncovered. Karla is a long-standing leader in bioethics and data transparency in the pharmaceutical industry. As part of the Office of the Chief Medical Officer at Johnson & Johnson, she brings deep expertise in navigating the ethical implications of emerging technologies, especially artificial intelligence, in medicine and drug development.In this episode, Tim and Karla explore the intersection of AI, bioethics and patient-centered development. They discuss how existing ethical frameworks are being challenged by the rise of generative AI and why maintaining human oversight is critical—especially in high-context areas like clinical trial design, consent and medical communications. Karla also shares her views on the future of data privacy, the complexity of patient agency and how to avoid losing trust in the race for efficiency.Karla is a strong advocate for using innovation responsibly. From her work with internal bioethics committees to her perspective on evolving regulatory expectations, she offers bold insights into how the industry can modernize without compromising ethics or equity.Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries. With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product.

In the latest collaboration between ACRO and TransCelerate BioPharma, Cris McDavid (Senior Director, Global Clinical Operations, Parexel) and Tashan Mistree (Senior Director, Business Operations, Office of Chief Medical Officer, GSK) join this week's episode to discuss the impact of ICH E6(R3) from their different vantage points in the clinical research industry. They dive deeper into their experiences implementing the new guidance at their respective companies, the new opportunities that R3 has created in the partnership between CROs and sponsors, and how they envision the future state of R3 once industry has fully embraced the guidance. FIND ACRO & TRANSCELERATE'S ICH E6(R3) TOOLS & RESOURCES HERE: https://www.acrohealth.org/initiatives-hub/interpreting-ich-e6r3/ 

In this powerful and emotional episode, we welcome special guest Jen, who bravely shares the story of her husband Mike's eight-year battle with brain cancer—a journey marked by resilience, heartbreak, and unwavering love.Through years of surgeries, research, second opinions, and clinical trials, Jen and Mike did everything they could to fight the disease. In the midst of the uncertainty, they were gifted with a beautiful daughter, who became a beacon of hope and strength.Eventually, when there options were available exhausted, they made the courageous choice to shift from fighting the disease to fully living the time they had left together. Jen opens up about what it means to love deeply, grieve honestly, and honor someone's life by continuing to move forward.This is a story of grace in the face of pain, and what it means to truly live—even when time is limited.Follow us on IG for more:https://www.instagram.com/spillinitpodcast?igsh=MWM1ZTZncDBiczZ4Mg%3D%3D&utm_source=qrhttps://www.instagram.com/thecortreport?igsh=NWxsaDdkOXRhbm56&utm_source=qrhttps://www.instagram.com/grayed_early?igsh=MWRwZ2VodzRmaHZuNA%3D%3D&utm_source=qrhttps://www.instagram.com/jena0614?igsh=Y2JoanphM2ZzbmFpHave an inspiring story you would like to share? Fill out the following Questionnaire and we will be in touch.Resources:

Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics. In this episode, recorded live at the European Association for the Study of the Liver Congress (EASL) in Amsterdam, Tom shares invaluable insights into the evolving landscape of hepatology clinical trials and the unique challenges and opportunities shaping the field today. Listen now to stay ahead in the dynamic world of clinical trials.

Send us a textDr. Michael Koren joins Kevin Geddings to discuss how Knowledge is Power - especially when it comes to medicine. The doctor explains how diagnostic tests like high sensitivity C-reactive protein (HSCRP) empower physicians and patients by giving insight into heart attack and stroke risk. Dr. Koren also tells us that even simple things like knowing you are in a research study can improve patient outcomes, and that knowledge is the guiding principle in medicine.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In this episode of It Takes Balls, Dr. Nabil Adra, a medical oncologist at Indiana University Health and leading researcher in testicular cancer care explores everything from recurrence and refractory disease to the latest advancements in treatment and monitoring.Dr. Adra breaks down risk categories that guide treatment - good, intermediate, and poor - and explains how factors like tumor type and blood markers shape decisions about chemo, surgery, or surveillance. He also dives into the science behind relapse and platinum resistance.A major highlight of the episode is the discussion of innovative diagnostic tools like circulating tumor DNA (ctDNA) and microRNA-371. These biomarkers are making it possible to detect microscopic cancer earlier and more accurately, with the goal of reducing overtreatment and improving outcomes.Dr. Adra also shares insights on long-term monitoring, including the reality of late relapse, and emphasizes why annual checkups are crucial - even decades after treatment. For those with relapsed or refractory disease, he offers a hopeful look at cutting-edge therapies including targeted treatments, high-dose chemo, and upcoming CAR-T cell trials.Have a question for a future expert guest? Submit here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-question-submissionWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgEmail Dr. Adra:nadra@iu.eduFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

Saudi Arabia's modern healthcare system, diverse patient population, and research-savvy healthcare professionals make it a great place to conduct clinical trials. To learn more about the clinical trial requirements in Saudi Arabia, I invited Professor Majed Al Jeraisy on the show.   Dr. Al Jeraisy is an Associate Professor of Pharmacy Practice, College of Pharmacy, King Saud Ben Abdulaziz University for Health Sciences and Pediatric Clinical Pharmacy Consultant in King Abdullah Specialized Children Hospital. He was appointed as the chairman of the research office at King Abdullah International Medical Research Center (KAIMRC) in 2007 and was appointed as the Director of Clinical Trial Services in 2018.  Please join me in welcoming Professor Majed Al Jeraisy on the Clinical Trial Podcast. This podcast is brought to you by Slope. Slope drives operational excellence for highly complex, sample-intensive, early-phase clinical trials. The platform transforms chaotic clinical trial supply chains into protocol-specific operational workflows for sponsors, CROs, clinical research sites and labs. Learn more at https://www.slopeclinical.com/ This podcast is brought to you by Florence Healthcare. Florence eliminates chaotic workflows in clinical research operations with remote access and digital workflow platforms. More than 12,000 study sites, sponsors, and CROs in 45 countries trust them to accelerate their operations. To learn more, visit https://florencehc.com 

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Shreyas Becker, Head of AI & Data Products, Manufacturing & Supply at Sanofi. Shreyas joins Emerj Managing Editor Matthew DeMello to discuss the practical application of AI in life sciences, focusing on tools that are already improving supply chain resilience and manufacturing efficiency. He explains how AI helps navigate geopolitical disruptions, optimize production workflows, and ensure the reliable delivery of critical medications. The conversation also covers the evolution of AI systems developed during the pandemic and their role in shaping future innovations. For pharma and life sciences professionals, Shreyas provides valuable insights into where AI is delivering impact today and the continuing importance of human expertise in these processes. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! This episode is sponsored by Arkestro. Learn more about Arkestro's upcoming Advisory Council event here. Find out more about sponsored content and how to engage with the Emerj audience at emerj.com/ad1.

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.